Kornimate/medical-research-clean huggingface dataset:
trust game and placebo response

Conditions: Placebo Effect; Pain; Trust

Summary: in the proposed study, investigators aim to investigate the role of interpersonal trust in the conditioned placebo analgesia process with healthy male subjects in a standardized experimental heat pain paradigm.


Eligibility criteria:
inclusion criteria: * men: age between 18 and 40 years old * healthy by self-report statement, thus no known current or chronic somatic diseases or psychiatric disorders * right-handedness (oldfield, 1971) * willing to participate in study exclusion criteria: * any acute or chronic disease (chronic pain, hypertension, heart disease, renal disease, liver disease, diabetes) as well as skin pathologies, neuropathies or nerve entrapment symptoms, sensory abnormalities affecting the tactile or thermal modality * current medications (psychoactive medication, narcotics, intake of analgesics) or being currently in psychological or psychiatric treatment * insufficient german language skills to understand the instructions * previous participation in studies using pain assessment (threshold and tolerance) with peltier devices * daily consumption of more than three alcoholic standard beverages per day (a standard alcoholic beverage is defined as either 3dl beer or 1 dl wine or 2cl spirits * current or regular drug consumption (thc, cocaine, heroin, etc.)
a multicenter randomized controlled study of 3d laparoscopy versus endoscopy in the treatment of choledocholithiasis

Conditions: Choledocholithiasis; ERCP

Summary: the incidence of choledocholithiasis is gradually rising with the increase of gallstone incidence. the popular minimally invasive treatment options include endoscopic retrograde cholangiopancreatography (ercp) and laparoscopic common bile duct exploration (lcbde). currently, three-dimensional (3d) video system for laparoscopy is developed to ofer surgeon a superior depth perception and a much better user experience, thus potential increasing operation accuracy and stability. it have suggested that compared with 2d laparoscopy, 3d laparoscopy can effectively reduce operation time and numbers of errors. however, rare experimental studies are performed to evaluate the safety and effectiveness of 3d laparoscopy in choledocholithiasis patients. the aim of this study is to compare the perioperative outcomes between 3d laparoscopy and ercp in choledocholithiasis patients through a multicenter randomized controlled design.


Eligibility criteria:
inclusion criteria: 1. the diagnosis of choledocholithiasis based on preoperative image studies including abdominal ultrasonography, computed tomography (ct), and/or magnetic resonance cholangiopancreatography (mrcp) with relevant supporting laboratory examinations 2. age \ 18y 3. non-emergency surgery exclusion criteria: 1. diagnosis of mirizzi's syndrome, 2. acute suppurative cholangitis 3. detection of bilioenteric anastomosis 4. pathological diagnosis of cholangiocarcinoma 5. extended surgery due to multiple biliary strictures, 6. intrahepatic stones
delivery timing in morbidly adherent placentas: a randomized, controlled trial

Conditions: Morbidly Adherent Placenta; Placenta Accreta

Summary: this is a randomized controlled trial to investigate the optimal timing of delivery in clinically stable women with a suspected morbidly adherent placenta.

this is a randomized controlled trial to investigate the optimal timing of delivery in clinically stable women with a suspected morbidly adherent placenta dispositioned for a scheduled delivery. the primary outcome will be assessed by comparing the composite neonatal morbidity and composite maternal morbidity between the two groups (delivery at 34 versus 36 weeks gestational age).

Eligibility criteria:
inclusion criteria: * women with monographically morbidly adherent placenta with or without a placenta previa. * scheduled delivery via cesarean hysterectomy exclusion criteria: * delivery planned prior to 36 weeks (e.g. non-reassuring fetal status, preterm labor, severe preeclampsia, other medical/fetal indication for delivery as determined by the managing physician).

Keywords: placenta accreta morbidly adherent placenta
a study for evaluation of immunogenicity and reactogenicity of fluarix/influsplit ssw 2012/2013 in people aged 18 years and above

Conditions: Influenza

Summary: the purpose of this study is to assess the immunogenicity and safety of gsk biologicals' trivalent influenza vaccine manufactured for the 2012/2013 influenza season administered in adults (18 to 60 years) and in elderly (over 60 years).


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes can and will comply with the requirements of the protocol. * a male or female aged 18 years or above at the time of vaccination. * written informed consent obtained from the subject. * healthy subjects or subjects with well-controlled chronic diseases as established by medical history and clinical examination before entering the study. * female subjects of non-childbearing potential may be enrolled in the study. * female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of vaccination. exclusion criteria: * use of any investigational or non-registered product other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs within the six months prior to vaccination. inhaled and topical steroids are allowed. * administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or planned administration during the study period. * administration of an influenza vaccine within the six months preceding the study vaccination. * planned administration/ administration of a vaccine other than the study vaccine within 30 days before study vaccination and during the entire study period. * clinically or virologically confirmed influenza infection within the six months preceding the study vaccination. * acute disease and/or fever at the time of enrolment. * acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * chronic underlying disease, not stabilized or clinically serious. * history of chronic alcohol consumption and/or drug abuse. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * history of guillain-barré syndrome. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * anaphylaxis following the administration of vaccine(s). * pregnant or lactating female. * female planning to become pregnant or planning to discontinue contraceptive precautions. * any condition which, in the opinion of the investigator, prevents the subject from participating in the study.

Keywords: influenza healthy immunogenicity elderly safety adults
the effect of embryo transfer technique on pregnancy outcomes in hrt-fet cycles

Conditions: Infertility

Summary: the positions of the air bubble and the tip of catheter will be measured by transabdominal utrasonography among patients who have undergone high-quality frozen blastocyst transfer. the aim of this study is to compare pregnancy rates according to air bubble's final location in endometrial cavity. it is expected that the et technique will be improved and live birth rates will increase by determining the optimal position of the embryo in the endometrial cavity during et in patients who have achieved pregnancy.

only patients who have high-quality blastocyst stage embryos will be included in the study. since the implantation potential of high-quality embryos is high, possible embryo-induced implantation failure will be minimized. the positions of the air bubble and the catheter in the endometrial cavity in patients with and without pregnancy will be compared. in patients participating in the study, the transfer catheter will be loaded using a "three drop technique," in which the drop of medium containing the embryo(s) is/are separated from a preceding and a following drop of the medium by an air bubble. in hormonally prepared frozen embryo cycles, during embryo transfer in each patient, endometrial thickness, uterine cavity dimensions, distance of transfer catheter to the fundus, distance of released air bubble to the fundus, and distance of air bubble to side walls will be systematically measured and recorded under the guidance of transabdominal ultrasonography. if the position of the embryo in the endometrial cavity is determined during et in patients who have achieved pregnancy, an et technique can be defined that predicts the optimum for the physician who will perform the transfer. therefore, an increase in implantation and pregnancy rates can be achieved.

Eligibility criteria:
inclusion criteria: * exogenous hormone preparation of the endometrial lining * high embryo quality ((≥2bb) according to alpha criteria * embryo transfer at the blastocyst stage exclusion criteria: * patients whose treatments were canceled for any reason before the embryo transfer procedure * patients who underwent embryo transfer in the cleavage stage * presence of low-quality (\<2bb) blastocysts * \>15% loss of viability of the embryo during embryo thawing, * patients with congenital uterine malformations,

Keywords: air bubble position embryo transfer ultrasonographic guidance
in-field detection of intracranial pressure

Conditions: Traumatic Brain Injury

Summary: this is a research study to develop a noninvasive test using ultrasound to determine when urgent, life-saving treatment is needed for those with severe traumatic brain injuries.


Eligibility criteria:
healthy volunteer inclusion criteria: * adults 18 or older * able to provide legally effective consent healthy volunteer exclusion criteria: * intracranial disease, neurologic symptoms, or eye pathology patient inclusion criteria: * adults age 18 or older * confirmed or suspected severe traumatic brain injury * able to provide legally effective consent patient exclusion criteria: * significant bilateral ocular trauma
comparison of the efficacy and safety of two topical creams for pediatric atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this study compares the effectiveness of two topical creams for atopic dermatitis in pediatric subjects. subjects will be randomly assigned to use one of the two creams twice daily for 6 weeks or until clear.


Eligibility criteria:
inclusion criteria: * at least 3 months of age and less than 13 years of age * atopic dermatitis of moderate severity exclusion criteria: * pregnant or lactating * treatment of atopic dermatitis with topical product in the 14 days prior to baseline * treatment of atopic dermatitis with systemic product in the 30 days prior to baseline * serious or uncontrolled medical condition * active infection * significant use of inhaled, intranasal, or intraocular corticosteroid
study to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels

Conditions: Myocardial Infarction; Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack); Unstable Angina; Angina; Ischaemic Heart Disease

Summary: this study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels. researcher will collect information about the percentage of time a patient has access to the medication, how long patients continue with the medication and of the proportion of patients who switch from dual-antiplatelet therapy (including low-dose aspirin) to a single antiplatelet therapy. the study will make use of secondary healthcare data sources converted in to observational medical outcomes partnership (omop) common data model within the observational health data sciences and informatics (ohdsi) network.


Eligibility criteria:
inclusion criteria: * aged ≥18 years * patients will be selected if they have at least two prescriptions for low-dose aspirin (75-100 mg) between 2008 and 2018 for either: * primary prevention of cvd this is defined as patients who have no history of cvd any time prior to initiation of low-dose aspirin treatment are presumed to use for primary cvd prevention * secondary prevention of cvd this is defined as patients who have a history of cvd any time prior to initiation of low-dose aspirin treatment * patients with at least two prescriptions of low-dose aspirin with a dosage of 75-100mg within the first year of the index date. * restricted to patients with observation for at least 12 months before and 12 after the index date. exclusion criteria: - prescription of low-dose aspirin in 12 months before the index date.
assessment of telehome monitoring in patients on peritoneal dialysis: a multicentre randomized controlled trial

Conditions: End-Stage Renal Disease

Summary: compared to hemodialysis, patients on peritoneal dialysis live longer and healthier, have a higher quality of life and cost approximately $40,000 less to the healthcare system per patient per year. however, only 18% of dialysis patients in canada currently use peritoneal dialysis because patients often feel isolated from the healthcare team and lack the confidence to manage treatments by themselves. this study will assess a telehome monitoring system (eq connect™), allowing for up-to-date data transmission and digital interaction between the patients at home and their healthcare team. from the patients' perspective, this technology is an easier way to communicate with their healthcare providers, track their treatment and supplies, and receive training and support. from the providers' perspective, eq connect™ delivers up-to-date patient data and provides an efficient way to keep track of the patients' progress. this intervention has the potential to improve the patients' clinical outcomes, quality of life, reduce the costs of dialysis to the healthcare system and ultimately empower patients to start and stay on peritoneal dialysis.


Eligibility criteria:
inclusion criteria: 1. able to provide informed consent 2. patient or primary care giver able to read and speak english 3. over 18 years of age 4. patient on pd (apd/capd) for at least 3 months 5. patient or primary care giver cognitively and physically capable and willing to interact with a tablet computer and perform self-measurements (e.g. taking weight) exclusion criteria: 1. scheduled kidney transplant within 1 year (identified, processed and medically worked out their donor) 2. life expectancy \<1 year (estimated by physician) 3. in long-term care facility 4. deemed unable to comply with the telehome monitoring support system (e.g. due to vision problems, literacy, lack of manual dexterity to accurately interact with the tablet, or decreased cognitive function such as memory loss) by physician 5. participating in another interventional trial that could influence the intervention or outcome of this trial 6. was in another interventional trial that could influence the intervention or outcome of this trial, ≤4 weeks prior to recruitment 7. patients on hybrid dialysis (those on both peritoneal dialysis and hemodialysis)

Keywords: end-stage renal disease peritoneal dialysis telehomecare telehome monitoring
target therapy with gemox in recectable gallbladder carcinoma patients monitored by ctdna

Conditions: Gallbladder Carcinoma

Summary: the purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with gemox in recectable gallbladder carcinoma patients monitored by ctdna.

genomic profiling studies the deoxyribonucleic acid (dna) of a tumor to detect genetic changes or abnormalities. immuno-histochemistry tests reveal the abnormal activation status of signal pathways involved in study. these information will be used to recommend target therapy which may be more likely to result in a beneficial response. patients will receive target antitumor agents according to the result of genomic and proteomic profiling and be monitored by circulating tumor dna(ctdna).

Eligibility criteria:
inclusion criteria: * chinese# * stable vital signs, ecog:0-1; * patients have a diagnosis of resectable gallbladder carcinoma by histopathology or cytopathology after radical surgery. * adequate fresh tumor tissue for genome sequencing and immunohistochemistry test; harboring mutations or abnormal activation of erb-b2 receptor tyrosine kinase signal pathway components * life expectancy of more than 18 weeks; * t stage≥ t2 or histopathological lymph node positive according to ajcc (8th edition) staging. * adequate hepatic, hematologic and renal functions(alt≤5×upper limit of normal (uln), ast≤5×uln, the child-pugh classification for class a or b, white blood cells≥3×10\^9/l, neutrophils≥1.5×10\^9/l, platelets≥75×10\^9/l , hemoglobin ≥ 90g/l, creatinine clearance rate≥60ml/min; * volunteer for this study, have written informed consent and have good patient compliance; * female patients of childbearing potential and their mates agree to avoid pregnancy. exclusion criteria: * have received following treatment before this study: a. anti-tumor molecular target therapy; anti-tumor chemotherapy in 6 months; b. lesions have been treated by irradiation; c. participate in other therapeutic or interventional clinical trials. * history of other malignancies except carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and other malignancies for more than 5 years; * have serious concurrent illness including, but not limited to uncontrolled congestive heart failure(nyha classification grade iii or iv), unstable angina pectoris, unstable cardiac arrhythmias, uncontrolled moderate or serious hypertension(systolic blood pressure \>21.3 kpa or diastolic blood pressure \>13.3 kpa); * have ongoing or active serious infection; * have uncontrolled diabetes mellitus; * psychiatric illness which potentially hamper the ability to willingly give written informed consent and compliance with the study protocol; * active autoimmune diseases require long-term use of steroids or received allotransplantation * other serious illness considered not suitable for this study by investigators.
using salt to improve micronutrient status

Conditions: Neural Tube Defects; Folic Acid Deficiency; Spina Bifida; Anencephaly-Spina Bifida

Summary: question: how effective is folic acid-fortified iodized salt in increasing serum folate concentrations among non-pregnant and non-lactating women of reproductive age? hypothesis: folic acid-fortified iodized salt can increase serum folate levels and serve as a policy consideration in salt fortification with both iodine and folic acid to reduce serious and fatal birth defects.

salt is an ideal vehicle for fortification because its universal consumption and often centrally processed with established distribution channels. over 70% of households globally have access to iodized salt. considering the success of salt iodization, it is logical to use the existing infrastructure to provide folic acid through this dietary mechanism. aim:to assess increase in blood folate concentrations among women of reproductive age after they consume folic acid-fortified iodized salt. objectives : 1. to examine the effect of consumption of salt fortified with folic acid on serum/plasma folate concentrations among women of reproductive age. 2. to assess acceptance of study salt for daily use during 3 months of consumption.

Eligibility criteria:
inclusion criteria: • willing to voluntarily participate in the study * can comprehend and comply with study requirements * aged between 18 and 45 years. * no documented issues with child bearing potential * resident of the area of study for duration of study. * consume only study salt during study exclusion criteria: * taking multivitamins or fa during study * pregnant or lactating at recruitment or during study * co-morbidities such as malabsorption disorders, severe anemia (hgb \<8.0 g/dl), uncontrolled hypertension, (sbp ≥140 mm hg or dbp ≥90 mm hg), hiv, active tb or malaria infection * history of prior sba delivery * pre-existing medical conditions (i.e., cancer or need for regular medications)
dexmedetomidine and adenosine: therapeutic use for svt

Conditions: Supraventricular Tachycardia

Summary: the purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the acute termination of supraventricular tachycardia (svt).

in 2006 the investigator found that dexmedetomidine, an alpha-2 adrenergic agonist with primarily sedative properties, possesses additional anti-arrhythmic properties. so far the investigator has found that dexmedetomidine has the ability to prevent or terminate arrhythmias like atrial ectopic tachycardia (85% success) and junctional ectopic tachycardia (75% success). the most dramatic effect however was observed in the acute termination of reentrant svt with a success rate of \> 96%. more importantly we found that dexmedetomidine terminates svt without causing any sinus pause or asystole (frequently seen with adenosine) and thus avoiding the feeling of "impending doom". in this study adenosine is being compared head to head with dexmedetomidine in a cross over study, for both safety and efficacy when given for the termination of svt in the electrophysiology (ep) lab. additional ep parameters will be measured to elucidate the exact site of dexmedetomidine's mechanism of action.

Eligibility criteria:
inclusion criteria: * patients between the age of 5 - 30 years old, who are scheduled for cardiac electrophysiology study for evaluation of reentrant svt exclusion criteria: * severe heart failure * presence of of any other antiarrhythmic medication within 24 hours of enrollment * third degree heart block * sick sinus syndrome

Keywords: supraventricular tachycardia svt reentrant tachycardia dexmedetomidine adenosine
preventing lymphedema in axillary lymph node dissection

Conditions: Lymphedema; Breast Cancer; Melanoma

Summary: the researchers are trying to answer if axillary reverse mapping (arm) with lympho-venous bypass (lvb) in patients undergoing an axillary lymph node dissection reduces the rate and severity of post-operative lymphedema of the arm.

all subjects will undergo an axillary lymph node dissection (alnd). cluster randomization will determine which of these subjects will have the arm with lvb and which subjects will have the alnd without this technique. as a baseline, all subjects will have the circumference of their arms measured and complete a questionnaire about lymphedema. performing the measurements and answering a questionnaire will be repeated at 6, 12, 24, and 36 months after surgery.

Eligibility criteria:
inclusion criteria * patients scheduled to undergo an axillary lymph node dissection * patients who in the surgeon's judgement are at high risk to convert to an axillary lymph node dissection based intraoperative findings * english speaking exclusion criteria * prior ipsilateral axillary lymph node dissection * prior ipsilateral axillary radiation * patients undergoing sentinel lymph node biopsy only or at low risk of converting to an axillary lymph node dissection in the surgeon's judgement * previous treatment for lymphedema of either arm or prescribed prophylactic treatment for lymphedema. * pregnant patients cannot participate in the substudy

Keywords: axillary lymph node dissection reverse mapping lympho-venous bypass (lvb) axillary reverse mapping (arm)